Ifp Advisors, Inc Monopar Therapeutics Transaction History

Ifp Advisors, Inc

  • $2.42 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Sep 06, 2022
BUY
$1.85 - $2.72 $925 - $1,360
500 New
500 $13,000
Q2 2022

Aug 12, 2022
SELL
$1.85 - $2.72 $925 - $1,360
-500 Closed
0 $0
Q1 2022

Sep 06, 2022
BUY
$2.5 - $3.62 $1,250 - $1,810
500 New
500 $0

About Monopar Therapeutics

MNPR Quotes by TradingView
  • Ticker MNPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,725,800
  • Market Cap $316M
  • Description
  • Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...
More about MNPR
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email